WuXi Biologics (Cayman)
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. WuXi Biologics (Cayman)'s past years’ income statements indicate that its last revenue has increased compared to the previous period by 12% to $17,034,255,000. Profit margin reached 20%. Total operating expenses were $2,878,437,999.

Profit Margin

WuXi Biologics (Cayman) Inc. (OTC:WXXWY): Profit margin
2014 331.85M 41.97M 12.65%
2015 557.04M 44.50M 7.99%
2016 989.02M 141.09M 14.27%
2017 1.61B 252.62M 15.61%
2018 2.53B 630.59M 24.88%
2019 3.98B 1.01B 25.45%
2020 5.61B 1.68B 30.09%
2021 10.29B 3.38B 32.93%
2022 15.26B 4.42B 28.95%
2023 17.03B 3.39B 19.96%

WXXWY Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
17.03B15.26B10.29B5.61B3.98B2.53B1.61B989.02M557.04M331.85M
Cost of revenue
10.20B8.54B5.46B3.07B2.32B1.51B958.27M599.91M376.32M208.59M
Gross profit
6.82B6.72B4.82B2.53B1.65B1.01B660.55M389.11M180.72M123.25M
Operating exp.
Research and development
792.57M689.57M507.83M308.97M260.95M169.28M74.47M53.28M39.74M35.02M
Selling and marketing
294.00M162.91M124.64M94.41M77.08M42.43M27.62M15.32M13.44M4.30M
Total operating expenses
2.87B1.41B854.61M605.33M588.21M368.80M329.92M189.52M120.84M72.33M
Operating income
3.94B4.35B3.17B1.50B947.96M522.37M410.69M225.89M62.22M52.81M
Other income (expenses), net
224.33M1.00B823.05M463.72M178.66M215.34M-107.00M-50.05M3.17M-3.80M
Income before tax
4.17B5.35B3.99B1.96B1.12B737.72M303.68M175.84M65.40M49.01M
Income tax expense
603.17M807.86M484.53M273.06M116.29M107.25M51.05M34.75M20.89M7.03M
Net income
3.39B4.42B3.38B1.68B1.01B630.59M252.62M141.09M44.50M41.97M
Earnings per share
Basic EPS
0.771.060.810.430.270.160.070.040.020.02
Diluted EPS
0.781.010.770.40.250.160.070.040.020.02